{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:16:41Z","timestamp":1787930201000,"version":"build-2784847793"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.clinthera.2022.05.003","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T13:03:02Z","timestamp":1654866182000},"page":"957-970.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Impact of Mandatory Nonmedical Switching From Originator to Biosimilar Insulin Glargine"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9730-5107","authenticated-orcid":false,"given":"Anat","family":"Fisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Dormuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.05.003_bib0001","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/dci18-0007","article-title":"Economic costs of diabetes in the U.S. in 2017","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.clinthera.2022.05.003_bib0002","doi-asserted-by":"crossref","first-page":"49","DOI":"10.24095\/hpcdp.37.2.03","article-title":"The cost of diabetes in Canada over 10 years: applying attributable health care costs to a diabetes incidence prediction model","volume":"37","author":"Bilandzic","year":"2017","journal-title":"Health Promot Chronic Dis Prev Can."},{"key":"10.1016\/j.clinthera.2022.05.003_bib0003","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.2337\/dc19-2273","article-title":"Factors contributing to the rising national cost of glucose-lowering medicines for diabetes during 2005-2007 and 2015-2017","volume":"43","author":"Zhou","year":"2020","journal-title":"Diabetes Care"},{"issue":"13","key":"10.1016\/j.clinthera.2022.05.003_bib0004","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/jama.2016.0126","article-title":"Expenditures and prices of antihyperglycemic medications in the United States: 2002-2013","volume":"315","author":"Hua","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0005","unstructured":"Patented Medicine Prices Review Board. Potential savings from biosimilars in Canada. 2017. http:\/\/pmprb-cepmb.gc.ca. Accessed March 9, 2021."},{"key":"10.1016\/j.clinthera.2022.05.003_bib0006","unstructured":"CADTH Therapeutic Review. New drugs for type 2 diabetes: second-line therapy \u2013 science report. 2017. https:\/\/cadth.ca\/drugs-type-2-diabetes-second-line-therapy-review-update. Accessed August 26, 2021."},{"key":"10.1016\/j.clinthera.2022.05.003_bib0007","unstructured":"Berger J. Biologics in Canada, part 1: market trends, 2018 (table 2.1). 2020. https:\/\/www.canada.ca\/en\/patented-medicine-prices-review\/services\/reports-studies\/biologics-part1-market-trends.html. Accessed January 4, 2021."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2022.05.003_bib0008","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jval.2018.04.488","article-title":"Budget impact analysis of basaglar for the treatment of type 1 and type 2 diabetes in patients eligible for a long-acting insulin analog","volume":"21","author":"Bly","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0009","first-page":"372","article-title":"Implementation of biosimilar uptake: a cost minimization study for insulin glargine","volume":"41","author":"Mehring","year":"2019","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0010","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1186\/s12913-019-4680-2","article-title":"Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis","volume":"19","author":"Mansell","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0011","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nbt.1936","article-title":"Biosimilars-why terminology matters","volume":"29","author":"Weise","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0012","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/cpt.1836","article-title":"The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review","volume":"108","author":"Barbier","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195012","article-title":"Efficacy and safety of biosimilar insulins compared to their reference products: a systematic review","volume":"13","author":"Tieu","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0014","first-page":"6","article-title":"Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2","volume":"7","author":"DeLozier","year":"2018","journal-title":"GaBI J"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0015","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/0897190019853957","article-title":"Impact of dosing conversion from basal insulin to follow-on insulin glargine","volume":"34","author":"Maes","year":"2021","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0016","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1177\/1060028020903816","article-title":"Real-world evaluation of dosing in patients converted from insulin glargine (Lantus) to insulin glargine (Basaglar)","volume":"54","author":"Pitlick","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0017","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/03007995.2020.1754182","article-title":"Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study","volume":"36","author":"Shingaki","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0018","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1080\/03007995.2020.1834374","article-title":"Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: a post-marketing safety study","volume":"36","author":"Taki","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2022.05.003_bib0019","first-page":"22","article-title":"Insulin glargine and hypersensitivity reactions as an example of biosimilars pharmacovigilance","volume":"29","author":"Ali","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0020","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.3390\/ijerph17165800","article-title":"Clinical and regulatory concerns of biosimilars: a review of literature","volume":"17","author":"Halimi","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.clinthera.2022.05.003_sbref0021","series-title":"Diabetes, biologic drugs, and biosimilar insulins \u2014 Position statement","author":"Diabetes Canada","year":"2019"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0022","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jama.2019.2990","article-title":"Trends in Medicaid prices, market share, and spending on long-acting insulins, 2006-2018","volume":"321","author":"Hernandez","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0023","unstructured":"British Columbia Ministry of Health \u01c0 PharmaCare. Limited coverage drug (LCD) program. 2021. https:\/\/www2.gov.bc.ca\/gov\/content\/health\/practitioner-professional-resources\/pharmacare\/prescribers\/limited-coverage-drug-program. Accessed December 21, 2021."},{"key":"10.1016\/j.clinthera.2022.05.003_bib0024","unstructured":"British Columbia Ministry of Health \u01c0 PharmaCare. Biosimilars initiative insulin glargine. https:\/\/www2.gov.bc.ca\/assets\/gov\/health\/health-drug-coverage\/pharmacare\/patient-info-insulin-glargine_final.pdf. Accessed October 19, 2021."},{"key":"10.1016\/j.clinthera.2022.05.003_bib0025","unstructured":"British Columbia Ministry of Health. Fair PharmaCare plan. https:\/\/www2.gov.bc.ca\/gov\/content\/health\/health-drug-coverage\/pharmacare-for-bc-residents\/who-we-cover\/fair-pharmacare-plan. Accessed August 12 2021."},{"key":"10.1016\/j.clinthera.2022.05.003_bib0026","unstructured":"Health Canada. Canada's health care system. 2011. https:\/\/www.canada.ca\/en\/health-canada\/services\/health-care-system\/reports-publications\/health-care-system\/canada.html#a5. Accessed January 25, 2021."},{"key":"10.1016\/j.clinthera.2022.05.003_bib0027","unstructured":"First Nations Health Authority. Benefits. https:\/\/www.fnha.ca\/benefits. Accessed August 11, 2021."},{"key":"10.1016\/j.clinthera.2022.05.003_bib0028","unstructured":"British Columbia Ministry of Health \u01c0 PharmaCare. What is a deductible? in fair PharmaCare plan https:\/\/www2.gov.bc.ca\/gov\/content\/health\/health-drug-coverage\/pharmacare-for-bc-residents\/who-we-cover\/fair-pharmacare-plan. Accessed March 9, 2021."},{"key":"10.1016\/j.clinthera.2022.05.003_bib0029","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1177\/193229681100500303","article-title":"Identifying type 1 and type 2 diabetic cases using administrative data: a tree-structured model","volume":"5","author":"Lo-Ciganic","year":"2011","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0030","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0031","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/2229-3485.179436","article-title":"Common pitfalls in statistical analysis: the perils of multiple testing","volume":"7","author":"Ranganathan","year":"2016","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0032","series-title":"A Likelihood Paradigm","year":"1997"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0033","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/oxfordjournals.aje.a116700","article-title":"P values, hypothesis tests, and likelihood: implications for epidemiology of a neglected historical debate","volume":"137","author":"Goodman","year":"1993","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0034","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/pds.4957","article-title":"A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia","volume":"29","author":"Dormuth","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0035","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/pds.5008","article-title":"Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbia-an interim report","volume":"29","author":"Fisher","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0036","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/dom.13904","article-title":"Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: results of the INSTRIDE 3 phase 3 switch study","volume":"22","author":"Blevins","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0037","doi-asserted-by":"crossref","first-page":"477","DOI":"10.12688\/f1000research.13923.1","article-title":"Switching from biosimilar (Basalin) to originator (Lantus) insulin glargine is effective in Chinese patients with diabetes mellitus: a retrospective chart review [version 1; peer review: 3 approved, 1 approved with reservations]","volume":"7","author":"Hu","year":"2018","journal-title":"F1000 Res"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0038","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40744-019-00190-7","article-title":"Nonmedical switching from originators to biosimilars: does the nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology?","volume":"7","author":"Fleischmann","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2022.05.003_bib0039","first-page":"306","article-title":"Persistence in rheumatoid arthritis patients on biosimilar and bio-originator etanercept: a pooled analysis of Pancanadian cohorts","volume":"79","author":"Moura","year":"2020","journal-title":"ARD"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249453","article-title":"Patient access to chronic medications during the covid-19 pandemic: evidence from a comprehensive dataset of US insurance claims","volume":"16","author":"Clement","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0041","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2337\/cd18-0105","article-title":"Standards of medical care in diabetes-2019 abridged for primary care providers","volume":"37","author":"American Diabetes Associate","year":"2019","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0042","unstructured":"British Columbia Ministry of Health \u01c0 PharmaCare. PharmaCare newsletter, edition 19-003. 2019. https:\/\/www2.gov.bc.ca\/assets\/gov\/health\/health-drug-coverage\/pharmacare\/newsletters\/news19-003.pdf. Accessed June 8, 2021."},{"key":"10.1016\/j.clinthera.2022.05.003_bib0043","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001016","article-title":"Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? a Danish register-based study of patients with inflammatory arthritis","volume":"5","author":"Glintborg","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.clinthera.2022.05.003_bib0044","doi-asserted-by":"crossref","first-page":"753","DOI":"10.55563\/clinexprheumatol\/pa6lap","article-title":"Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons","volume":"39","author":"Convertino","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2022.05.003_bib0045","first-page":"835","article-title":"Economic outcomes, treatment patterns, and adverse events and reactions for patients prescribed infliximab or CT-p13 in the Turkish population","volume":"76","author":"Phillips","year":"2017","journal-title":"ARD"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822001540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822001540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:56:25Z","timestamp":1758963385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822001540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0149291822001540"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.05.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Mandatory Nonmedical Switching From Originator to Biosimilar Insulin Glargine","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}